Eversept Partners LP increased its stake in Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) by 21.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 305,233 shares of the company’s stock after acquiring an additional 54,801 shares during the period. Deciphera Pharmaceuticals makes up about 2.0% of Eversept Partners LP’s holdings, making the stock its 13th largest holding. Eversept Partners LP owned about 0.80% of Deciphera Pharmaceuticals worth $6,883,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in DCPH. Bank of Montreal Can purchased a new position in Deciphera Pharmaceuticals in the second quarter valued at $28,000. BNP Paribas Arbitrage SA grew its holdings in shares of Deciphera Pharmaceuticals by 61,033.3% during the first quarter. BNP Paribas Arbitrage SA now owns 1,834 shares of the company’s stock worth $43,000 after purchasing an additional 1,831 shares during the last quarter. Tower Research Capital LLC TRC purchased a new position in shares of Deciphera Pharmaceuticals during the second quarter worth about $64,000. JPMorgan Chase & Co. grew its holdings in shares of Deciphera Pharmaceuticals by 89.2% during the second quarter. JPMorgan Chase & Co. now owns 4,057 shares of the company’s stock worth $95,000 after purchasing an additional 1,913 shares during the last quarter. Finally, Virtus ETF Advisers LLC grew its holdings in shares of Deciphera Pharmaceuticals by 17.7% during the second quarter. Virtus ETF Advisers LLC now owns 12,449 shares of the company’s stock worth $281,000 after purchasing an additional 1,871 shares during the last quarter. Institutional investors and hedge funds own 45.68% of the company’s stock.
In other news, Director Michael Douglas Taylor sold 7,500 shares of Deciphera Pharmaceuticals stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $36.26, for a total transaction of $271,950.00. Following the completion of the sale, the director now directly owns 7,500 shares in the company, valued at approximately $271,950. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Thomas Patrick Kelly sold 11,250 shares of Deciphera Pharmaceuticals stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $41.27, for a total transaction of $464,287.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 539,534 shares of company stock valued at $20,465,526. 7.02% of the stock is owned by insiders.
NASDAQ:DCPH traded up $0.38 during mid-day trading on Friday, reaching $36.86. The stock had a trading volume of 1,103 shares, compared to its average volume of 1,088,560. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.26 and a current ratio of 7.26. The firm has a market capitalization of $1.79 billion, a price-to-earnings ratio of -13.07 and a beta of 1.92. Deciphera Pharmaceuticals Inc has a twelve month low of $18.55 and a twelve month high of $42.99. The business has a 50 day simple moving average of $30.99 and a 200 day simple moving average of $25.60.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings data on Friday, August 2nd. The company reported ($0.56) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.12) by $0.56. The firm had revenue of $25.00 million during the quarter, compared to analyst estimates of $20.00 million. As a group, sell-side analysts expect that Deciphera Pharmaceuticals Inc will post -4.21 earnings per share for the current year.
Several brokerages have issued reports on DCPH. Canaccord Genuity reaffirmed a “buy” rating and set a $65.00 price objective (up previously from $50.00) on shares of Deciphera Pharmaceuticals in a report on Wednesday, August 14th. BidaskClub raised Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 16th. Piper Jaffray Companies increased their target price on shares of Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Monday, June 3rd. They noted that the move was a valuation call. SunTrust Banks increased their target price on shares of Deciphera Pharmaceuticals to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Finally, Cantor Fitzgerald increased their target price on shares of Deciphera Pharmaceuticals from $43.00 to $55.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $48.00.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Further Reading: Equal Weight Rating
Want to see what other hedge funds are holding DCPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Deciphera Pharmaceuticals Inc (NASDAQ:DCPH).
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.